According to the company, this approval marks the first time an immuno-oncology therapy has demonstrated a survival benefit for all adults with primary advanced or recurrent endometrial cancer.
FDA expands approval of GSK’s Gemperli in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial cancer
Leave a comment
